Journal of Medical Economics
Volume 23, 2020 - Issue 11
Diabetes
Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective
Johan Jendlea Institute of Medical Sciences, Örebro University, Örebro, SwedenCorrespondence[email protected]
https://orcid.org/0000-0003-1025-1682
https://orcid.org/0000-0003-1025-1682, , Bertil Ekmanc Department of Endocrinology, and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Swedenhttps://orcid.org/0000-0001-8732-7361
https://orcid.org/0000-0001-8732-7361, , , , Ann-Charlotte Mårdbyb Novo Nordisk Scandinavia AB, Malmö, Swedenhttps://orcid.org/0000-0003-0579-3583
https://orcid.org/0000-0003-0579-3583, Barnaby Huntf Ossian Health Economics and Communications, Basel, Switzerlandhttps://orcid.org/0000-0001-5420-279X
https://orcid.org/0000-0001-5420-279X, Samuel J. P. Malkinf Ossian Health Economics and Communications, Basel, Switzerlandhttps://orcid.org/0000-0003-1306-7784
https://orcid.org/0000-0003-1306-7784 & Maria Thunanderf Department of Clinical Sciences, Endocrinology and Diabetes, Lund University, Lund, Swedenhttps://orcid.org/0000-0001-6888-1295
https://orcid.org/0000-0001-6888-1295 show all